drugset / Trial / NCT07650266
A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma
Phase 1
Not yet recruiting
60 enrolled
Memorial Sloan Kettering Cancer Center
Regeneron Pharmaceuticals · collab
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to find out whether cemiplimab, with or without fianlimab, is an effective treatment for advanced nasopharyngeal carcinoma (NPC), when given with standard chemotherapy drugs gemcitabine and cisplatin before standard chemoradiation.
Timeline
- Start
- 2026-07
- Primary completion
- 2030-07
- Completion
- 2030-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | — | — |
| Comparator | Fianlimab | Monoclonal antibody | — | — |